NEW YORK (GenomeWeb) – ArcherDx has partnered with HeliTec on the development of next-generation sequencing-based cancer diagnostics for the Chinese market, the companies announced today.
Under the terms of the deal, the companies will codevelop and cross-license certain NGS technologies with the goal of registering oncology diagnostic kits with the China Food and Drug Administration. In addition, all of ArcherDx's NGS assays — including its FusionPlex RNA assays, VariantPlex DNA assays, Reveal ctDNA 28 kit, and Immunoverse T-cell receptor kit — are now available from Shenzhen-based HeliTec.
The companies noted that HeliTec is also currently evaluating the Reveal assay to identify oncogenic mutations in liquid biopsies in a recently announced large-scale clinical study.
Additional terms of the deal were not disclosed.
"We are pleased to work with Archer to co-develop cutting-edge, NGS-based diagnostic assays in China, particularly on those cancer types predominant in Asian populations," HeliTec CEO Dongbin Zhou said in a statement.